£
Donate
Donate

In this research project, Dr Mishto wants to understand whether we might be able to harness our immune system to treat MPN.

Project information

Lead researcher

Dr Michele Mishto, King's College London

Research team
  • A team at King's College London
Related conditions
  • Myeloproliferative neoplasms (MPN)
Research type
  • Non-clinical
Region
  • London
Grant awarded
  • Project Grant
Status
Ongoing
Funding award date
January 2022
Amount awarded

£248,000

The challenge

Myeloproliferative neoplasm (MPN) is a type of blood cancer that is rarely curable and can sometimes progress into an aggressive type of blood cancer called acute myeloid leukaemia.

Whilst people can live many years with MPN, their quality of life is often reduced compared to someone without MPN and there’s a need to produce kinder and more effective treatments for these people.

The project

Dr Mishto and team know that getting the number of cancerous cells in the blood below a certain level can significantly improve the quality of life for people with MPN, and they want to find new ways to treat the disease that does this.

The team are going to study whether we can use treatments that harness our own immune system to do this and to destroy MPN cells.

I found this project investigates an important aspect of blood cancer.

- Patient Voice Grant Advisory Network Member, living with an MPN.

The future

This project could lead to new treatments being developed for MPN which are more effective and improve people’s quality of life. Ultimately, this would give people with MPN the best possible chance of survival.

Help us beat blood cancer by funding a research project

  • Could help eight people newly diagnosed with blood cancer understand their condition.
  • Could help researchers study blood cancer cells to develop new treatments and improve early diagnosis.
  • Could help scientists identify genetic patterns in tumour samples to better understand how genes contribute to the development of blood cancer.
Donate